Ocular Therapeutix, Inc. OCUL
6.66 USD +0.05 (+0.76%)
At closeNov 12, 2026, 4:50 AM EST
6.84 +0.18 +2.70%
Pre-market · Nov 12, 4:50 AM ET
6.48 Day range 6.82
6.00 52-week range 16.44
- YTD
- -45.14%
- 1 year
- -42.04%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28 HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $25 to $28.
seekingalpha.com Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript
marketbeat.com What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call Ocular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said…
zacks.com Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.37 per share a year ago.
benzinga.com Ocular Therapeutix Q3 2026 Earnings Call Transcript Ocular Therapeutix (NASDAQ:OCUL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 10.53 percent decrease over losses…
globenewswire.com Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting,…
globenewswire.com Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina…
benzinga.com Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
benzinga.com UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14 UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.